INVESTIGATING THE INFLUENCE OF OXIDATIVE STRESS AND THE ROLE OF

PRDX1 IN THE REGULATION OF LYSYL OXIDASE MEDIATED ECM AND

COLLAGEN REMODELING IN BREAST CANCER METASTASIS by Attaran, Shireen
  
Title Page  
Investigating the Influence of Oxidative Stress and the Role of Prdx1 in the Regulation of 
Lysyl Oxidase Mediated ECM and Collagen Remodeling in Breast Cancer Metastasis 
 
 
 
 
 
 
 
by 
 
Shireen Attaran 
 
B.S., University of California Davis, 2007 
 
M.S., California State University East Bay, 2013 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
 
School of Medicine in partial fulfillment 
  
of the requirements for the degree of 
 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
 
 
2018
 ii 
Committee Membership Page  
UNIVERSITY OF PITTSBURGH 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Shireen Attaran 
 
 
It was defended on 
 
September 17, 2018 
 
and approved by 
 
Patrick Pagano, Professor, Molecular Pharmacology 
 
Guillermo Romero, Professor, Molecular Pharmacology 
 
Lance Davidson, Professor, Bioengineering 
 
Yi Huang, Assistant Professor, Molecular Pharmacology 
Dissertation Director: Carola Neumann, Associate Professor, Molecular Pharmacology  
 iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © by Shireen Attaran 
 
2018 
 
 
 
Abstract 
 iv 
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Shireen Attaran, PhD 
 
University of Pittsburgh, 2018 
 
 
 
 
Breast cancer progression and metastasis includes not only cell-autonomous properties of 
cancer epithelial cells, but also the influence of the neighboring tumor stromal cells. In breast 
cancer, almost 80% of stromal associated fibroblasts (SAFs) acquire a cancer associated fibroblast 
(CAF)-like “activated phenotype”. This CAF activated phenotype is associated with elevated 
levels of reactive oxygen species (ROS) that are linked with tumor remodeling and spreading. 
Members of the lysyl oxidase (LOX) family of enzymes participate in tumor remodeling through 
the promotion of collagen crosslinking and collagen fibril production. We hypothesize that stromal 
Prdx1 regulates ROS dependent metastasis/migration of cancer cells through effects on LOX 
activity. Our preliminary data reveal that Prdx1 prevents CAF-induced malignant phenotypes in 
breast cancer (epithelial) cells in an H2O2-dependent manner. When compared to wild-type mice, 
Prdx1-/- SAFs show a marked increase in CAF-specific characteristics, including increased 
expression of CAF-specific markers, motility and invasiveness of SAFs and SAF-induced 
chemotactic migration and invasion by breast cancer epithelial cells in vitro. Lack of Prdx1 in 
mammary SAFs results in the upregulation of markers of the activated phenotype, such as 
collagen, vimentin and α-SMA leading to an increase in co-migration and invasion. As shPrdx1 
SAFs show CAF-like mesenchymal properties in vitro, we tested in vivo if Prdx1 suppresses 
migration of breast cancer 
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cells by generating a syngeneic mouse model to image BALB/c derived SAFs shPrdx1/SAFs 
pLKO1 (expressing iRFP). Immunoprecipitation data suggests that Prdx1 associates with LOX 
family proteins. Moreover, Prdx1-deficient SAFs displayed elevated LOX secretion into the ECM  
compared to Prdx1-proficient SAFs. Lastly, of translational relevance, we have shown that SAF 
Prdx1 becomes inactivated by cancer cells through phosphorylation of Y194 Prdx1. The 
peroxidase, Prdx1, is a regulator of LOX and CAF activity and SAFs lacking Prdx1 may serve as 
a valuable model system to investigate the biology of CAFs in vitro and in vivo. 
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1.0 Introduction 
1.1 Breast Cancer 
Breast cancer is the most common malignant disease in US women, with over 250,000 new 
cases and over 70,000 deaths expected in 2018 alone1. In these patients, it is not the primary tumor, 
but rather, the metastases to distant sites in the body that prove fatal2. More recently, the rates of 
mortality due to breast cancer have been declining due to enhanced mammographic screening and 
adjuvant therapies; however, chemotherapy has a host of both acute and long-term side effects and 
in some cases, it can even promote metastasis2, 3. Novel tools to predict chemotherapeutic benefit 
personalized to the patient, such as Oncotype DX4, are just now beginning to emerge; however, to 
date there are no tools available that can accurately predict which patients will progress to 
metastatic disease. The four main subtypes of breast cancer are 1) luminal A, 2) luminal B, 3) 
HER2 overexpressing and 4) triple negative breast cancer5. Luminal A breast cancer tends to be 
slow growing and less aggressive with a high survival rate. It is classified as being ER+, and/or 
PR+, and HER2-. Luminal B is characterized as being ER+, and/or PR+, and HER2+, with high 
proliferation rates and a poor prognosis compared to luminal A. HER2 overexpressing cancers 
tend to grow much more rapidly
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and spread more aggressively due to HER2+, ER+ and PR- classifications and lastly, the most 
aggressive form of the four is triple negative breast cancer, which has the worst prognosis among 
the four, with higher rates of recurrence after surgery and lack of targeted therapies currently 
available5. Ultimately deaths due to breast cancer are not a result of the primary tumor; instead 
they are due to the migration of these cancer cells to distant organs in the body, which is why an 
in-depth understanding of metastasis is critical to designing therapeutics to halt cancer progression 
and cancer-related deaths. 
1.2 Stromal microenvironment in breast cancer 
Cancer is a complex and systemic disease, which incorporates numerous components of 
both tumor and stromal cells embedded within the extracellular matrix (ECM)6-9. The 
microenvironment of a developing tumor is composed of proliferating tumor cells, tumor stroma, 
angiogenic interactions and immune responses and it is defined as the complex and dynamic 
interactions between cancer cells and the ECM10.  Furthermore, tumor associated macrophages 
(TAMs) play an important role in the secretion of growth factors, angiogenesis, tissue remodeling 
and the suppression of adaptive immunity. Additionally, bone marrow derived stem cells 
(BMDSCs); also secrete growth factors that can promote the differentiation of BMDSCs to 
osteoblasts, fibroblasts, chondrocytes and adipocytes. Primary and metastatic tumors are known 
to recruit BMDSCs to the microenvironment where they differentiate into tumor-associated 
fibroblasts, promoting tumor survival and persistence (Figure 1). 
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Several decades of in-depth cancer research has been focused on a tumor-cell autonomous 
view of cancer, however, more recently it has become apparent that tumor cells do not act alone, 
but rather, they persist in a fertile tumor microenvironment which is governed by tumor-stroma 
interactions to promote metastasis and cancer progression7, 11-16. As the cancer continues to evolve, 
the surrounding tumor stroma and ECM is also transformed into an activated state which is 
maintained by continuous paracrine signaling between the tumor cells and the host stroma, thereby, 
cultivating an environment permissive to cancer progression 10, 11.  
Fibroblasts were first identified by Virchow and Duvall in 1858, as cells that function to 
synthesize collagen in connective tissues17, 18. Phenotypically, fibroblasts are spindle-shaped, 
which can become polarized with migratory signaling. In normal tissues, fibroblasts are thought 
to be in a dormant state because of their relatively low metabolic activity19.  Quiescent fibroblasts 
are generally found in the interstitial stromal layers between the parenchyma and mature tissues 
and they are identified as being long, thin cells with a spindle-like shape19. Currently, quiescent 
cells are defined by their ability to respond to stimuli, such as growth factors, allowing them to 
become activated, thus prompting proliferation, migration, further production of growth factors 
and deposition of ECM proteins11, 19, 20. Once activated, these fibroblasts display significantly 
increased contractile and metabolic activity, which are critical components of wound repair and 
connective tissue production; in cancer, however, these typically normal processes become 
dysregulated19.   
If there is chronic inflammation or wound insults, either in the context of physical, toxic, 
autoimmune or metabolic disorders, the repair response will continue unrestricted, resulting in a 
condition called tissue fibrosis11, 19, 21. This process is thought to occur by epigenetic mechanisms
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 intrinsic to fibroblasts in the activated state, thus enriching anti-apoptotic signals and enhancing 
proliferation to generate over-activated fibroblasts19, 20.  
In the context of cancer, the tumor stroma is mainly comprised of fibroblasts; many studies 
to date have established that fibroblasts residing in the tumor microenvironment have a significant 
influence on cancer progression and invasion9, 12-14, 16, 22-24. Fibroblasts in the tumor 
microenvironment become activated and are termed, cancer associated fibroblasts (CAFs)13, 21, 25, 
26. Fibroblasts at basal state are typically quiescent; however, they become activated in response 
to wound healing20. Tumors are commonly referred to as wounds that will not heal because of 
aberrant wound healing responses27.  
Dysregulation of wound healing results from signaling responses which remain elevated 
and sustained even once the wound is resolved; this is typically observed in tissue fibrosis and 
tumor progression20, 27. CAFs are generally identified by their expression of α-smooth muscle actin 
(α-SMA), a cytoskeletal protein typically found in smooth muscle cells19. The mechanism 
governing fibroblast activation is still not fully understood; however, it has been shown that 
reversion of phenotype and behavior of malignant cells can be modified by altering the tumor 
ECM28, 29. This suggested that tumor cells do not act autonomously; rather, they are governed by 
stromal signaling in the tumor microenvironment. 
Early studies in the 1970s described a mechanism by which cancer cells recruit activated 
fibroblasts that are functionally similar to myofibroblasts associated with wound healing30, 31. This 
recruitment is largely regulated by growth factors secreted by the primary cancer cells and immune 
cells. TGF-β, PDGF and FGF-2 are the main mediators of activation in fibroblasts in both acute 
and chronic tissue damage and repair19. Furthermore, the recruitment of activated fibroblasts in 
many cancers is regulated by TGF-β32. Moreover, of importance when examining ECM matrix 
 5 
influences on metastasis, TGF-β, has been shown to increase the activity of lysyl oxidase (LOX), 
the primary enzyme responsible to collagen crosslinking and remodeling33 
 
 
 
Figure 1 Tumor Microenvrionment The tumor microenvironment is composed of a variety of different 
factors, which have the primary purpose of sustaining tumor vitality and promoting cancer progression. Bone 
marrow derived stem cells (BMDSCs) function to secrete growth factors allowing the differentiation into a 
variety of call types such as fibroblasts, osteoblasts and adipocytes. Macrophages are also recruited to the 
microenvironment and secrete growth factors that promote cancer progression while also suppressing innate 
adaptive immune responses. Activated fibroblasts in the microenvironment function to modify the ECM by 
altering the structure of collagen. 
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1.2.1  Lysyl Oxidase and Implications in Cancer 
Lysyl oxidase (LOX) and its family members, the LOX-like protein LOXL1-4 are copper 
dependent amine oxidases, which function to oxidize the ε-amino group of the peptidyl lysine to 
peptidyl aldehydes, subsequently followed by formation of dehydrolysinonorleucine and aldol 
condensation products from peptidyl aldehydes and lysine residues34, 35. Essentially, they are ECM 
enzymes, which function to catalyze collagen crosslinking in the stroma of the ECM, thus directly 
influencing the tensile strength of tissues36. All five of the LOX family members are highly 
conserved at the C-terminal catalytic domain; this includes the copper binding site, the lysyl tyrosyl 
quinine domain (LTQ) and the cytokine receptor like domain (CRL) (Figure 2). The copper and 
LTQ domains are absolutely essential to the oxidase activity of the LOX family member 
enxymes35, 37, 38. Copper is not directly involved with the catalytic component of LOX, however, 
it is crucial for maintenance of the LTQ domain and the conformation of the LOX protein34. 
The LTQ domain functions to maintain a negative charge in the LTQ pocket promoting 
copper recruitment; the LTQ domain is covalently linked via K314 and Y349 residues36. The LOX 
family members have significant differences on the N-terminus; LOXL1 contains a proline-rich 
domain and LOXL2, LOXL3 and LOXL4 contain four scavenging receptor cysteine-rich domains 
(SRCR)36. The SRCR region is frequently found at the cell surface and is thought to be involved 
in protein-protein interactions. The LOX family members are synthesized as zymogens in the 
endoplasmic reticulum. The pro-peptides are secreted into the ECM and the NH2-terminal pro-
peptide of LOX is cleaved by bone morphogenic protein-1 (BMP-1), thus allowing for enzyme 
activation and functioning oxidase activity35, 36 
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Figure 2 LOX Family Domains All members of the LOX family have a conserved C-terminal domain, which 
contains the catalytic domain responsible for providing the enzymatic crosslinking activity of the enzyme. 
Differences in family members can be seen on the N-terminal domain. LOXL2-LOXL4 all contain a 
scavenging receptor cysteine-rich (SRCR) domain. LOX and LOXL1 contain a pro-sequence domain. 
 
 
Once in the extracellular space and cleaved by BMP-1, LOX is in its active form and it can 
participate and catalyze crosslinking events of ECM protein such as collagen and elastin. These 
crosslinking reactions catalyzed by LOX provide tensile strength and integrity to connective 
tissues and also participate in wound repair cascades35, 39. Meticulous regulation of expression and 
activity of LOX is critical to sustaining tissue homeostasis. When dysregulation of LOX occurs, 
the pathogenesis of diseases such as tissue fibrosis and cancer arise35. LOX is regulated by a variety 
of pathways including transcriptional regulation and both temporal and spatial distributions, 
thereby modulating enzyme activity34.  
A critical cytokine responsible for regulating the ECM is TGF-β; it functions by regulating 
both ECM structural protein expression and via direct influences on ECM remodeling enzymes 
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such as LOX34, 35. TGF-β has been shown to increase LOX mRNA expression in a time and dose-
dependent fashion via PI3K and MAPK signaling40. In cardiac fibrosis, it has been shown that high 
doses of TNF-α results in LOX expression, causing an increase in collagen crosslinking and 
leading to an elevation in detrimental fibrosis41.  
LOX function is of critical importance to maintain normal homeostasis. Mice lacking LOX 
were described to be perinatal lethal, exhibiting ruptured diaphragms, arterial aneurysms, and 
disjointed elastic fibers42. The two most widely studied genetic diseases of copper metabolism are 
Menke’s and Wilson’s disease, which present with strikingly low levels of LOX activity due to 
the consequence of copper deficiency43. In these conditions, there is a marked decrease in fiber 
elasticity resulting in weakening of the structural integrity of tissues43. In a striking contrast, LOX 
activity is markedly upregulated in atherosclerosis, liver cirrhosis, and schleroderma44, 45. 
LOX is widely accepted as a poor prognosis factor, specifically in promoting metastasis in 
breast cancer34, 46, head and neck squamous cell carcinoma47 and lung48 and prostate cancer16 
(Table 1). In the context of breast cancer, it is important to understand that increased expression 
of LOX has been observed in invasive basal breast cancer, however, this elevation of LOX is not 
observed in non-invasive breast cancers49. Normal development in the mammary gland is mediated 
via GATA-3, a transcription factor that regulates differentiation of luminal cells and also 
negatively regulates LOX via methylation of the LOX promoter49. Furthermore, the transcription 
factor forkhead box M1b (FOXM1b), directly binds to the promoter of both LOX and LOXL2, 
leading to increased expression and activating the Akt/SNAIL pathway, leading to an elevation in 
liver fibrosis and metastasis of hepatocellular carcinoma; FOXM1b is overexpressed in human 
cancers and is correlated with poor prognosis49. Another critical regulator of LOX expression is 
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dependent upon hypoxia. In conditions of hypoxia, LOX mRNA is significantly upregulated via 
the transcription factor HIF1α47.  
The biomechanical properties of the tumor microenvironment have a critical role and 
influence on the behavior of cells residing in the microenvironment and there is a significant body 
of evidence highlighting the importance of collagen as the primary protein governing the 
mechanical component of the microenvironment37, 50-53. Recent studies have suggested that 
increased ECM protein deposition resulting in elevated tissue stiffness, steers cancer progression 
to metastasis, primarily via actinomyosin and cytoskeletal rearrangements, cellular contractions 
and altered growth factor signaling37, 51-54. To date, the mechanism behind this phenomenon has 
not yet been completely elucidated; however, more evidence has emerged suggesting that collagen 
crosslinking by the LOX family members have a critical role in supporting and promoting 
metastatic disease37, 52, 53, 55, 56.
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Cancer Family Role Ref. 
Breast LOX Increased expression correlated 
with increased metastasis and 
overall poor prognosis 
57-59 
 LOXL2 Increased expression in tumor 
stroma compared to normal stroma 
 
48, 60-62 
Colorectal LOX Increased expression= increased 
invasion, metastasis and SRC 
activation 
63, 64 
 LOXL2 Increased expression in tumor 
stroma 
 
64 
Lung LOXL2 Increased expression= Poor 
prognosis 
 
48 
Hepatocellular  
 
LOXL2 Increased expression in tumor 
stroma 
 
65 
Basal and 
squamous skin 
cell carcinoma 
 
LOX Decreased expression= increased 
invasiveness 
 
66 
Pancreatic 
 
LOXL2 Increased expression in tumor 
stroma 
 
67, 68 
Laryngeal 
 
LOXL2 Increased expression in tumor 
stroma 
 
69 
Table 1. LOX Family Members and Role in Cancers  
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1.2.2 Collagen Remodeling and Implications in Breast Cancer Metastasis 
Collagen is the most abundant protein in the body, representing approximately 30% of total 
mammalian protein mass and roughly 28 different forms of collagen have been identified in 
vertebrates70, 71. The primary structural component of the interstitial ECM is Type-I collagen, while 
in the basement membrane, Type IV collagen predominates playing a critical role in tissue 
polarity72. Collagen, being a fibrous protein which provides structural integrity to tissues, is 
composed of three polypeptide α-chains held together by hydrogen bonding, containing a 
polyproline, to form a right handed supercoil conformation73. The collagen triple helix provides a 
molecular conformation, which grants rigorous requirements of the amino acid sequence, 
demanding a Gly-X-Y repeating pattern73.  
Collagen endures vast post-translational modifications by crosslinking and hydroxylation 
reactions in the endoplasmic reticulum before the triple helix is formed. A wide variety of 
chaperones and enzymes assist the proper trimerization and folding of collagen73. Depending upon 
the structural properties of the ECM, collagen can form classic fibrillar fibers or network-forming 
collagens71. Among the many forms of collagen, collagen-I is the model fiber because its triple 
helix has no imperfections and it can self assemble into fibrils, while other variants of collagen 
cannot74. 
Under normal conditions of development such as branching morphogenesis of mammary 
ducts, epithelial cells interact with collagens in the ECM while also invading the basement 
membrane to pursue mammary gland expansion75. The same mechanism occurs in cancer cell 
progression, but in an aberrant and unregulated fashion. In many malignancies, desmoplasia is 
observed; this is defined as a robust fibrotic reaction characterized by a sustained deposition of 
fibrillar collagen I and III with an increased degradation of collagen IV19, 20, 56. In the setting of 
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breast cancer, increased incidence of these fibrillar collagens is correlated with poor prognosis; 
desmoplasia has been identified at metastatic sites functioning to support the successful 
establishment of metastases52, 56.  
In cancer, the structural integrity of the ECM withstands significant alterations during 
tumorigenesis, such as increased matrix cross-linking, deposition of fibronectin, proteoglycans and 
collagens I, III and IV. This progressive remodeling, which occurs during tumor evolution, creates 
a new, reorganized environment permissive to cancer progression by enabling the dysregulation 
of cell polarity, cell-cell adhesions and enhancing growth factor signaling76, 77. Furthermore, this 
architectural remodeling of the ECM results in morphological changes illustrated by the 
transformation of normal, curly collagen fibers to the formation of linearized interstitial collagen 
fibers at the invasion front of tumor progression77.  
In breast cancer, it has been long established that there is an important connection between 
cancer risk and breast density78. In normal, healthy epithelial tissues, the surrounding collagen is 
phenotypically curly and anisotropic. In progressive cancer, however, the collagen fibers undergo 
dramatic structural alterations; collagen fibers are transformed to linear, stiff fibers. This structural 
modification of collagen is ideal for the promotion of metastasis because it fosters the migration 
of tumor cells to the ECM51, 52, 54, 79. In a study conducted investigating the migratory patterns of 
breast cancer cells, intravital imaging showed that breast cancer cells and leukocytes do undeniably 
migrate along linearized collagen fiber highways80. More recently, better tools have been 
developed to characterize and classify architectural modifications in the ECM. Tumor associated 
collagen signatures (TACS) have been characterized to better define ECM architectural changes 
that occur in tumor progression. Using mouse models of breast cancer, initial changes in ECM 
architecture were observed as a localized increase of collagen deposition surrounding the tumor 
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border; this is termed TACS-1. As the tumor continues to grow and evolve, linearized collagen 
fibers begin to form tangent to the tumor border; this is defined as TACS-2.  As reorganization of 
the ECM progresses even further, the linear collagen fibers begin reorienting perpendicular to the 
tumor border; this is termed TACS-354. Further supporting these collagen signatures, studies 
conducted in the context of invasive breast cancer have shown that collagen is modified from a 
curly, anisotropic fiber to a stiff linear fiber. Moreover, at the invasive tumor border, linearized 
collagen fibers, perpendicular to the tumor edge can be visualized, further supporting the validity 
of TACS52-54, 81. 
1.3 Reactive oxygen species and Peroxiredoxin 1 
Reduction and oxidation (redox) chemistry is defined by reactions in which reduction 
causes a gain of electrons, while oxidation is represented by a loss of electrons. In biological 
systems, redox reactions can regulate intracellular levels of reactive oxygen (ROS) and nitrogen 
species (RNS) to control a multitude of intracellular processes. These reactive species include both 
radical and non-radical forms of ROS and RNS such as superoxide anion (O2●), hydrogen peroxide 
(H2O2), hydroxyl radical (●OH), nitric oxide (NO●), nitrogen dioxide (NO2●) and peroxynitrite 
(ONOO). The relative reactivity of these species spans several log orders of magnitude to affect 
the half-life and distance traveled within the intracellular environment. The hydroxyl radical is the 
most reactive species with a half-life on the order of 10-9 s, while H2O2 is much less reactive in 
comparison with a half-life of 10-3 s82. Many of these reactive species were initially regarded 
primarily as deleterious oxidants due to the recognition that an overabundance of ROS and RNS 
cause damage to DNA, proteins, lipids and carbohydrates. ROS and RNS were therefore thought 
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to require reduction to more inert forms in order to maintain intracellular homeostasis and prevent 
pathophysiological damage.  Further research has indicated that ROS and RNS play more complex 
roles in the cell with mounting evidence supporting a role for these species as mediators at lower 
concentrations to control protein function and coordinate cell-signaling pathways.  
There are diverse sources of ROS that emerge from several organelles within the cell. The 
intracellular concentration of H2O2 has been estimated to be on the order of 1 to 10 nM83 under 
basal conditions and reach 0.5 to 0.7 µM during oxidative signaling84. Mitochondria have been 
suggested to be a primary source of ROS due to the byproducts of oxidative phosphorylation to 
produce ATP. H2O2 production has been determined to arise from as much as 1-2% of the total 
oxygen utilized in isolated rat liver mitochondria during respiration85, but there is debate as to the 
magnitude86 and the concentration of H2O2 produced in vivo87. Complex I88, 89  and III90 produce a 
large proportion of the ROS generated within the mitochondria as O2●91, which is then reduced to 
H2O2 through catalytic dismutation by Mn-SOD92. The steady-state levels of O2●  have been 
suggested to be relatively low87 based on the enzymatic reaction rate (k = 109 M−1·s−1)93 and 
mitochondrial concentrations of MnSOD, which have been measured to be more than 10 µM in 
isolated rat liver mitochondria94. Other organelles that produce ROS include peroxisomes95 the 
endoplasmic reticulum85, 96 and lysosomes97. The plasma membrane and cytoplasm also produce 
ROS through the action of NADPH oxidase98, prostaglandin synthase99 , lipoxygenases100 and 
xanthine oxidase101 and transition metals102, respectively. All of these sources contribute to both 
the intracellular H2O2 load as well as the extracellular secretion of H2O2, which can reach 2 µM in 
stimulated neutrophils103.  
H2O2 is recognized as a particularly important reactive molecule with second messenger 
function. Spatiotemporal features of the molecule enable it to possess reactivity, yet move through 
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biological macromolecular microenvironments intracellularly within different organelle 
compartments and intercellularly to neighboring cells. Organ and cellular systems coordinate the 
balance of the H2O2 through enzymatic-catalyzed reductant proteins in conjunction with the pro-
oxidant sources mentioned above to form an interconnected network that maintains homeostasis 
or drives oxidative signaling. The enzymatic metabolism of H2O2 is primarily catalyzed through 
the action of catalase, glutathione peroxidases (GPx) and peroxiredoxins (Prdx). While all three 
enzymatically metabolize H2O2, important biochemical and biological differences exist. Insight 
into the basal function of the three enzymes in vivo can be drawn from the phenotypic effects 
observed in gene knockout studies. Deletion of catalase or GPx1 display no overt phenotypic 
changes under basal conditions in mice104, 105. This contrasts with the pathophysiological changes 
that exist upon deletion of Prdx1. Prdx1 knockout mice exhibit increased oxidative damage to 
DNA and cancer incidence at various sites throughout the animal as well as shortened lifespan and 
hemolytic anemia106. Deletion of the yeast Prdx homolog tsa1 has also been shown to have 
deleterious effects such as increased oxidative damage, thermosensitivity, mutagenesis and 
genomic instability107, 108. 
Catalase is localized within peroxisomes and catalyzes decomposition of H2O2 via an iron 
heme porphyrin complex109. Sequestration of catalase to a single organelle enables control of 
peroxisomal H2O2 levels, but also requires H2O2 derived from other intra and extracellular sources 
to diffuse to the peroxisome in order for catalase-dependent catalysis to occur. Catalase exhibits a 
high H2O2 turnover rate110, but sequestration in combination with other enzyme kinetic properties, 
such as a Km close to 100 mM in human erythrocytes110, yield an enzyme that is less effective 
when H2O2 concentrations are low. Contrasting catalase, GPx family members are not present in 
one organelle. There are eight family members in the glutathione peroxidases (GPx) family (GPx1-
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8). GPx1-4 utilize a selenocysteine active site and glutathione (GSH) as a co-factor to reduce 
H2O2111, 112. GPx1 and 4 are present in most tissues, with GPx1 expression found in the cytoplasm 
and mitochondria and the phospholipid hydroperoxide reducing GPx4 is found in the plasma 
membrane and cytoplasm112. Although GPx1 and 4 don’t display true Michaelis Menten kinetics, 
the second order rate constant of the two-part catalytic cycle is in the range of 105 M-1 s-1  112. 
The Prdx family has 6 members (Prdx1-6) that are present in many cellular compartments. 
Prdx1, 2 and 6 are located in the cytoplasm and nucleus; Prdx3 is localized to the mitochondria; 
Prdx4 is found in the endoplasmic reticulum; and Prdx5 is located in the peroxisomes, cytoplasm 
and mitochondria113. The Prdx family have 1 or 2-cysteine (Cys)-dependent reaction mechanisms 
to reduce H2O2 to water. The family is subdivided into groups classified as 2-Cys (Prdx1-4), 
atypical 2-Cys (Prdx5) and 1-Cys (Prdx6) isoforms based on their structure and mechanism of 
action114. The active site peroxidatic Cys is conserved among all family members at roughly 50 
amino acids from the N-terminus. The peroxidatic Cys is highly reactive to H2O2 due to 
surrounding amino acids with rate constants on the order of 106 to 108 M-1 s-1 115. 
Homodimerization of Prdx proteins in a N-terminus head to C-terminus tail fashion enables 2-Cys 
family members to align the peroxidatic Cys to the mechanistically important resolving Cys 
located on the opposing Prdx homodimerization partner near the C-terminus. Prdx1 and 2 
homodimers can associate non-covalently to form larger decameric complexes that is ordered as a 
pentamer of dimers to form a doughnut-like structure116, 117.  In 2-Cys Prdx, the peroxidatic Cys is 
oxidized by H2O2 to a sulfenic acid moiety, which then forms a disulfide bond with the resolving 
Cys on the homodimerization partner118, 119(Figure 2). The disulfide bound dimer destabilizes 
decameric Prdx to cause dissociation of the complex120, 121. The redox reaction cycle can be 
regenerated by reducing the formed homodimer disulfide bond with thioredoxin (Trx)117. The 
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peroxidatic Cys can become overwhelmed in the presence of high levels of H2O2 and become 
overoxidized to form Cys sulfinic or further sulfonic moieties that lack peroxidase activity. The 
rate constant of the sulfenic acid form of Prdx2 with H2O2 to form the sulfinic Prdx is on the order 
of 104 M-1 s-1122. The sulfinic form was found to be reversible via enzymatic reduction by 
sulfiredoxin protein123. In addition to the classic Trx recycling, a second redox cycle has recently 
been described for Prdx2. The sulfenic peroxidatic Cys can be adducted with GSH (rate constant 
500 M-1 s-1) under physiological concentrations to protect from overoxidation and recycle with 
Grx1124.   The atypical Prdx5 follows a similar reaction mechanism, but contrasts typical 2-Cys 
Prdx by forming an intramolecular disulfide bond with the resolving Cys as opposed to an 
intermolecular disulfide bond125, 126. The 1-Cys Prdx6 protein still forms homodimers, but does 
not form a disulfide bond following oxidation of the peroxidatic Cys and instead exists in the 
sulfenic acid form that is reduced with GSH127.  
The peroxidase activity of 2-Cys Prdx has been tied to redox sensor functions to control 
cell signaling pathways through protein coupling reactions128. Prdx2 has recently been shown to 
participate in a thiol disulfide exchange reaction with the transcription factor STAT3 to repress 
transcriptional activation129. The highly sensitive peroxidatic Cys of Prdx2 therefore acts akin to 
an oxidative receptor that transfers the oxidative signaling equivalents to a partnering target protein 
through a Cys redox relay. This mechanism enables the coordination of oxidative signaling to 
target proteins in the absence of high concentrations of H2O2 or highly reactive Cys elements in 
target proteins. Redox relays exist within the cytoplasm for Prdx1130and have been further 
investigated in larger scale studies. CRISPR-Cas9 deletion of the cytoplasmic Prdx family 
members Prdx1 and 2 in HAP1 cells showed that cells without Prdx1 or 2 had less oxidation of 
cytoplasmic protein thiols globally and further support the importance of the redox relay 
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hypothesis131. Other cellular compartments also show redox relay actions such as the ER for 
Prdx4132 and Gpx7133. This mechanism is currently under further exploration to resolve how many 
proteins, labeled as redox regulated, undergo oxidation with rate constants on the order of 10 to 
102 M-1 s-1134 outside of close proximity to an H2O2 generating source within a cellular environment 
with abundant highly reactive peroxidases. 
 
 
 
Figure 3. Reduction of H2O2 by Prdx1 Peroxiredoxins (Prdxs) are a family of small (22–27 kDa) non-seleno 
peroxidases currently known to possess six mammalian isoforms. Although their individual roles in cellular 
redox regulation and antioxidant protection are quite distinct, they all catalyze peroxide reduction of H2O2 
(1st step of cycle). In the 2nd step of the cycle, resolution of sulfenic acid is where they all differ. Prdx1 & 2 
both have catalytic Cys 52 and resolving cysteine, Cys 173. In the 3rd step of the cycle, Trx, regenerates the 
redox reaction cycle by reducing the homodimer disulfide bond. 
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Outside of oxidation of the peroW2wzzxidatic Cys in Prdx proteins other factors have been 
described to alter peroxidase activity and structure including local microenvironmental aspects 
such as pH135, ionic strength136, and temperature137. Post-translational modifications can affect 
peroxidase activity and structure and cell signaling coordination of Prdx activity is apparent 
through phosphorylation at different sites within the protein. Phosphorylation of Prdx1 to modulate 
structure and function are seen on Ser32, Thr90, Thr183 and Tyr194. A classic counter-example 
to the redox relay supported cell signaling coordination by Prdx described above is provided by 
phosphorylation of Tyr194 on Prdx1 by Src138. Local inactivation of Prdx1 peroxidase activity 
generates increased zonal concentrations of H2O2 through the action of Nox139 at the plasma 
membrane that is required to drive growth factor receptor tyrosine kinase signaling140, 141. 
Phosphorylation on Tyr194 in response to treatment of cells with EGF or PDGF displayed isoform 
selectivity for Prdx1 in comparison to Prdx2. Studies showed that siRNA knockdown or 
pharmacological inhibition of Src reduced the phosphorylation. The peroxidatic Cys was protected 
from overoxidation of phosphorylation protein during co-treatment of cells with growth factor and 
H2O2. In vitro studies of the phosphorylated protein found the dimeric form of the Prdx1 was 
present without decamers. In vivo wound healing experiments found that Tyr194 phosphorylation 
peaked after 1 day and remained for 1 week. 
Local H2O2 accumulation through inactivation of Prdx1 by phosphorylation is also 
important in the nucleus during mitosis142. During early mitosis Prdx1 bound to the centrosome is 
inactivated by Cdk1-cyclinB phosphorylation of Prdx1 at Thr90 to promote inactivation of the 
dual-specificity protein tyrosine phosphatase Cdc14B by elevated H2O2143. Inactivation of Cdc14B 
and possibly other mitotic exit phosphatases sensitive to inactivation by H2O2, enables active 
Cdk1-cyclin B to transition cells to late mitosis where Prdx1 can be dephosphorylated to promote 
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deactivation of Cdk1 via dephosphorylation by the now activated Cdc14B. The importance of 
centrosomal H2O2 during the transition to mitosis was evaluated by expressing catalase fused to a 
centrosomal targeting sequence, which inhibited entry into mitosis. Phosphorylation of the Thr90 
residue of Prdx1 by the kinase Mst1 and possibly Mst2 has also been described144. Mst1 in the 
full-length form is localized in the cytoplasm, but caspase cleavage causes nuclear translocation 
of the kinase145, whether Mst1 inactivation of Prdx1 is cell compartment generalized or specific to 
the nucleus or cytoplasm is unknown. Mst1 can additionally phosphorylate Thr183 in the C-
terminus of the Prdx1, which was shown to also inactivate peroxidase activity in vitro using site-
directed mutagenesis to yield Prdx1 Thr183Asp purified protein144. Expression of mutant Prdx1 
Cys183Asp protein in Prdx1-/- mouse embryonic fibroblasts (MEFs) showed heightened levels of 
the DNA damage biomarker phosphorylated Ser139 H2AX following treatment with H2O2. The 
inactivation of Prdx1 by Mst1 could potentially cause a positive feedback loop whereby excess 
H2O2 further activates Mst1. 
Phosphorylation is not only repressive of Prdx1 peroxidase activity. The T-cell-originated 
protein kinase (TOPK) can phosphorylate Prdx1 on Ser32 to enhance peroxidase activity 
(20647304). During a mass spectrometry investigation into proteins that bind TOPK in response 
to ultraviolet light B irradiation of RPMI7951 cells, Prdx1 was identified and following 
phosphorylation found to have reduced accumulation if H2O2 in vitro and ex vivo. In the absence 
of TOPK via siRNA decrease, cells were more sensitive to UVB-induced apoptosis. Melanoma 
cells expressing wild-type, but not Ser32Ala Prdx mutant, protein were more resistant to UVB 
irradiation. Whether Prdx2 can also be phosphorylated by TOPK is unknown, but may not be seen 
in experiments with RPMI7951 cells, which only express high levels of Prdx1.  
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As Prdx1 is not typically mutated in cancers (Table 2), it is critical to investigate the 
importance of post-translational modifications in the context of cancer. Phosphorylation of Prdx1 
on Y194 has been described in the context of wound healing138. Prdx1 associated with the cell 
membrane is transiently phosphorylated on Y194, thereby becoming inactivated in cells stimulated 
by growth factors or immune responses in vitro and at the margins of wound healing at cutaneous 
lesions in mice. This transient accumulation of H2O2 around cell membranes, where signaling 
components are concentrated, allows for localized inactivation of Prdx1 allowing H2O2-dependent 
signaling to take place without risking toxic accumulation of H2O2 at other sites where signaling 
components are absent, risking toxicity138. Moreover, in an analysis of clinical biosets, Prdx1 
expression was found to be higher in tumor-associated stroma compared to both normal epithelium 
and normal stroma (Table 3). 
 
 
 
Table 2. Comparison of mutation and deletion frequency of PRDX1-6 in various cancers TCGA data sets that 
are publicly available in the cBIOPortal  (www.cbioportal.org) were analyzed 
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Table 3. Prdx1 Regulation Across Selected Biosets Data was obtained using the BaseSpace Correlation 
Engine. Fold change of Prdx1 expression was measured from various different protein tissue expression data 
sets.  
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2.0 Identifying the role of Peroxiredoxin-1 in cancer associated fibroblast migration 
2.1 Introduction 
It is well established that fibroblasts within the tumor stroma acquire an activated 
phenotype, which is similar to the phenomenon observed in wound healing20, 146. In breast 
carcinomas, only about 20% of stromal fibroblasts maintain an un-activated phenotype; 
approximately 80% of stromal fibroblasts in the tumoral vicinity will gain this activated 
phenotype20, 146. These activated fibroblasts have been termed cancer-associated fibroblasts 
(CAFs) due to their nature and relationship to the primary tumor13, 20. Fibroblast activation is 
induced by a broad range of stimuli, which are activated upon tissue injury20. When epithelial cells 
endure injury, they release a wide variety of growth factors such as transforming growth factor-β 
(TGF-β), epidermal growth factor (EGF), platelet derived growth factor (PDGF) and fibroblast 
growth factor-2 (FGF-2). Additionally, fibroblasts can also become activated by direct cell-cell 
communication in addition to direct activation by reactive oxygen species or ECM alterations20. 
Activated fibroblasts are commonly referred to as myofibroblasts due to their expression of α-
smooth muscle actin (αSMA). Activated fibroblasts also secrete growth factors such as hepatocyte 
growth factor (HGF), insulin-like growth factor (IGF), nerve growth factor (NGF), EGF and FGF-
2. This increase in growth factor secretion can prompt the activation of proliferation in neighboring 
epithelial cells20. These growth factor secretion cascades observed in activated fibroblasts are of 
key importance in wound healing responses. In the context of wound healing, fibroblast activation 
is reversed back to the basal state once the activating stimulus from injury subsides20. In cancer, 
tumors are described as wounds, which do not heal because there is no observed reversion of 
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activation even when the initial activating stimulus is attenuated and at the molecular level, there 
is not yet a clear understanding of why and how this occurs13, 20, 27, 147. Fibroblasts in a sustained 
state of perpetual activation continue to secrete and deposit ECM proteins and growth factors 
resulting in an autocrine-loop stimulating the activation of nearby fibroblasts and preventing the 
conclusion of the initial injury stimulus13, 20, 147. The mechanism by which normal fibroblasts make 
the conversion to a CAF or their role in the initiation of cancer is still not well understood. 
However, initial studies have demonstrated that CAFs have the ability to affect the motility of 
cancer cells via secretion of growth factors into the ECM148.  Additionally, increased deposition 
of proteins intrinsic to the ECM, such as collagen and fibronectin, and tumor stromal expansion is 
often a characteristic of invasive carcinomas7. This increase in ECM deposition in tumors is termed 
desmoplasia; this is often observed in organ fibrosis14, 149. Fibrosis and desmoplasia are 
characterized by thickening and linearization of crosslinked collagen fibers. 
A critical step in the initiation of metastasis is the interaction between cancer and stromal 
cells at the borders of invasion of a perpetually expanding neoplasia. It has been described 
previously that the aggressiveness of a particular carcinoma is greatly dependent on the ability of 
malignant cells to recruit surrounding stromal cells and thereby transform them into CAFs22, 150-
152. During cancer progression, tumor cells modify the surrounding ECM and stroma via secretion 
of a variety of growth factors and paracrine signaling cascades, which results in the alteration of 
the microenvironment to a climate which is more favorable and conducive to the metastatic 
programming of the carcinoma153.  The role of CAFs promoting collective tumor cell invasion has 
been previously established22, 150-152, 154. A recent study showed that CAFs promote directional 
cancer cell migration by reorganizing and aligning fibronectin in the ECM21.  
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To build upon this theory of CAF induced tumor cell migration, we further examined ROS-
induced stromal fibroblast conversion into CAFs and we investigated Prdx1-mediated prevention 
of tumor initiation and progression. Previous studies conducted by our lab showed that mice 
lacking Prdx1 had shorted lifespans due to severe hemolytic anemia and the development of 
several cancers, including breast cancer106, 155-157. Currently the relationship between reactive 
oxygen species (ROS) and CAF development is not well described. Therefore, we found it 
imperative to better understand the mechanism by which Prdx1 and its mediation of ROS, 
influences CAF migration. We hypothesized that stromal Prdx1 is inactivated by a cancer-cell 
secreted factor, thereby, transforming normal fibroblasts to an activated, CAF-like fibroblast, 
rending these activated fibroblasts more migratory. 
2.2 Materials and Methods 
2.2.1  Fibroblast Isolation and Cell Culture Conditions  
Primary SAFs were isolated from female BALB/c mouse mammary glands. Female 
BALB/c mice were purchased from Jackson laboratory. Animals were housed in a pathogen-free 
facility in accordance with the Animal Care and Use Guidelines of the University of Pittsburgh. 
Mammary stromal fibroblasts were isolated from 8 to 12-week old virgin BALB/c female mice. 
Briefly, mice were sacrificed, and the mammary glands quickly removed, washed twice in wash 
solution (46 mL Dulbecco’s phosphate buffered saline (DPBS) (Sigma), 2.5mL FBS (Gibco), 100 
units/ml penicillin, 100 mg/ml streptomycin (Mediatech) and 400 µL Fungizone), and finely 
minced. Tissues were then disaggregated by repeated aspiration using a 10 ml syringe (no needle). 
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Tissues were then centrifuged and digested at 37 °C for 2 h in DMEM containing 10% FBS, 100 
units/ml penicillin, 100 mg/ml streptomycin (Mediatech), 3500 units/ml collagenase followed by 
a 10 min trypsin digestion step that was neutralized with FBS. Cells were then washed twice in 
PBS and plated in complete DMEM with 5% FBS. After 2 h, non-adherent cells were removed 
and the remaining fibroblasts were cultured for several weeks at 37 °C in a 5% CO2 and 5% oxygen 
until spontaneously immortalized. 
2.2.2  Lentivirus Preparation and Infection 
Lentivirus of pLKO.1 shRNA vector specific to Prdx1 was prepared in 293T HEK cells in 
OPTI-MEM Reduced Serum Media.  The shRNA Prdx1 target sequence used was,  
5’CCGGGCTCAGGATTATGGAGTCCTACTCGAGTAAGACTCCATAATCCTGAGCTTTT
TG-3’. Following 24 h, the media was exchanged to 10% FBS-DMEM media and virus was 
collected at 24 and 48 h. Parental SAFs were then infected with 8 μg/mL polybrene in the media. 
Following initial infection, medium was exchanged and 7 days post-infection cells were placed 
under puromycin selection (2 μg/mL) in 10% FBS-DMEM media.  
2.2.3  Immunoblot  
SAFs were lysed in a TRIS lysis buffer (50mM Tris; 2% Triton X-100; 0.5 mM EDTA; 
0.5 mM EGTA; 150 mM NaCl; 10% glycerol; 50 mM NaF; 1 mM NaVO4; 40 mM β-
glycerophosphate), supplemented with 30 μg/mL catalase from bovine liver (Sigma), and 
proteinase inhibitors. Protein concentrations were quantified using the Pierce BCA Protein Assay 
kit, according to the manufacturer’s instructions (ThermoFisher). Whole cell lysates were 
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fractionated by SDS-PAGE and transferred to a nitrocellulose membrane according to the 
manufacturer (BioRad). Membranes were blocked with 5% BSA in TBS for 2 h, and incubated 
with antibodies against Prdx1(1:1000)(Abcam), PRDX-SO3 (1:1000)(Abcam), and GAPDH 
(1:1000)(Abcam), overnight at 4 °C. Membranes were washed three times for 10 min in TBST 
(0.05% Tween-20), and visualized by infrared (IR) detection. For IR processing, membranes were 
incubated with a 1:15000 dilution of anti-goat, anti-rabbit, or anti-mouse IRDye (LI-COR), for 30 
min at 25˚ C. Blots were washed with TBST 3-times and with TBS once, and imaged on an 
Odyssey (LI-COR) imager.  
2.2.4  Immunofluorescence  
SAFs were seeded on glass cover slips and were fixed for 15 minutes in 3.7% 
paraformaldehyde, rinsed twice in cold PBS pH=7.4 for 10 min and permeabilized in blocking 
solution (PBS with 5% BSA and 0.3% Triton™ X-100) for 30 min. Cover slips were then washed 
twice in chilled PBS pH=7.4 for 10 min and specific primary antibodies (anti-collagen-1 
(Calbiochem), α-smooth muscle actin - Cy5 (Sigma-Aldrich), vimentin (Cell Signaling) were 
diluted 1:250 in antibody dilution buffer: (PBS with 5% BSA and 0.3% Triton™ X-100) were 
applied overnight at 4°C. Cells were washed twice in cold PBS pH=7.4 for 10 min and 
flourochrome-conjugated secondary antibodies (mouse or rabbit) Alexa Fluor® (Molecular 
Probes, Life Technologies) diluted 1:2000 in antibody dilution buffer were applied for 2 h at RT 
in the dark. To visualize DNA, after two 10 min washes, cells were stained with Hoechst 
(Molecular Probes, Life Technologies) for 15 min at RT in the dark. The slides were again rinsed 
in PBS and then the cover slips were mounted on microscope slides using Prolong® Gold Anti-
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Fade Reagent (Molecular Probes, Life Technologies). Images were obtained on an Olympus 
confocal microscope. 
2.2.5  Luminol Hypochlorite Assay 
Hydrogen peroxide was measured using a GloMax (Promega) with injectors from 200,000 
MFFs in a 12-well plate in 1 ml of serum-free DMEM utilizing a modified luminol/hypochlorite 
assay. Briefly, DMEM diluted with PBS to 25% was added to a 96-well plate and luminescence 
was measured by injecting luminol (Sigma) and sodium hypochlorite (Sigma) to final 
concentrations of 120 µM and 250 µM, respectively. Hydrogen peroxide concentrations were 
determined by comparison to experimental standard curves (0 to 100 µM). 
2.2.6  Transwell Migration Assay 
SAFs were starved in 0.25% FBS DMEM for 24 h at 37°C, 21% CO2. Cells were 
trypsinized, spun for 5 min at 1500xg and suspended in 0.25% FBS DMEM. Cells were counted 
and 2.5 x 104 fibroblasts in 0.25% FBS DMEM were seeded onto the membrane of the self-
standing Millicell Culture Plate Inserts (Millipore). 2 ml of 10% FBS DMEM was added to the 
bottom of the plate. The migration assay was carried out for 24 h at 37°C, 21% CO2. Following 
the 24 h migration, a damp cotton swab was used to wipe the non-migrated cells from the top of 
the transwell membrane. Cells were fixed with 2% paraformaldehyde for 15 min, washed twice 
with 1X PBS, and stained with 0.1% crystal violet. Numbers of migrating SAFs were visualized 
under a light microscope using 4X magnification. Images of the crystal violet stained membrane 
were quantified using ImageJ to assess number of migrating SAFs. 
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2.2.7  Statistical Analysis 
Student’s t-test was used to compare two groups. Data are presented as mean +/- SD. 
Statistical analyses were done using GraphPad Prism. p-value < 0.05 was considered significant 
2.3 Results 
2.3.1  Loss of Prdx1 in SAFs leads to increased migration  
Prdxs are a family of peroxidases ranging between 22-27 kDa and there are six known 
mammalian isoforms17, 18, 20. Although the individual roles among the isoforms are quite distinct, 
overall, they all catalyze the reduction of H2O2 to H2O via their peroxide function and they are all 
found to be ubiquitously expressed throughout the cell17-20. All aerobic organisms produce H2O2, 
as a byproduct of normal cellular metabolism. Due to its cellular toxicity, these organisms are 
equipped with detoxifying enzymes such as catalase, glutathione peroxidases and peroxiredoxins; 
these enzymes function to metabolize H2O2, thereby ameliorating cellular toxicity21. Although 
H2O2 is toxic to cells, it can provide a critical function as a signaling molecule via oxidation of 
critical cysteine residues of protein tyrosine phosphatases in response to cell surface receptor 
activation21.  
In the context of Prdx1, the active site cysteine is selectively oxidized to cysteine sulfinic 
acid rendering the peroxiredoxin inactive and unable to scavenge H2O222.  Oxidative stress in CAFs 
is known to drive tumor progression due to its influence on the stromal microenvironment and 
through the induction of genomic instability in neighboring cancer cells thereby elevating their 
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aggressive behavior; CAFs are much more genomically stable in comparison to epithelial cancer 
cells23. In breast cancer, loss of Cav-1 is one of the strongest stromal biomarkers associated with 
poor clinical prognosis.  
Cancer cells have been shown to induce ROS production in stromal fibroblasts, ultimately 
leading to a decrease in stromal Cav-1 expression23. Cancer cells have been shown to adopt 
compensatory mechanisms against excessive oxidative stress leading to cellular damage by 
upregulating antioxidant enzymes such as Prdx123. Previous studies from our group have described 
that the loss of Prdx1 in mice resulted in shortened lifespans due to the development of hemolytic 
anemia and variety of cancers including breast cancer17. Loss of H2O2 scavenging capabilities in 
stromal fibroblasts has yet to be fully understood and as a result, the data presented in this section 
will explore the phenotypic function that results from Prdx1 loss in stromal fibroblasts. We 
hypothesized that loss of Prdx1 in stromal fibroblasts would cause them to be more migratory and 
CAF-like (Figure 4). 
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Figure 4. Schematic Illustrating Loss of Prdx1 Stroma-Associated Fibroblasts (SAFs) are transformed into a 
CAF-like phenotype via the inactivation of Prdx1 in stromal fibroblasts, this is hypothesized to occur via a 
cancer-cell secreted factor. CI= catalytic inactivation 
 
 
2.3.2  Prdx1 is inactivated by hydrogen peroxide 
As discussed earlier, Prdx1 functions as a H2O2 scavenger. The peroxidase activity of 
Prdx1 can be irreversibly inactivated via exposure to high concentrations of H2O2. In Figure 5B, 
we show that with a 30 min, 100 μM dose of H2O2, there is overoxidation of Prdx1 to its Prdx1-
SO3 sulfonic form. At low concentrations of H2O2, stromal fibroblasts are able to continue with 
peroxide scavenging capabilities and the catalytic cysteine does not become overoxidized. 
However, with high concentrations of H2O2, a clear pattern emerges, control EV SAFs become 
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overoxidized on the catalytic residue of Prdx1 and begin to resemble shPrdx1 SAFs and are no 
longer able to scavenge and metabolize H2O2 (Figure 5A). 
 
Figure 5. High concentrations of H2O2 cause overoxidation of Prdx1 A) At 30 min, 100 μM H2O2 
treatment, scavenging ability of control SAFs resemble shPrdx1 SAFs B) 30 min treatment of BALB/c 
stromal fibroblasts with 100  and 250 μM H2O2 causes overoxidation of the catalytic cysteine in Prdx1 
rending it catalytically inactive and unable to scavenge excess H2O2. N=3 
 
 
2.3.3  Short hairpin knockdown of Prdx1 results in CAF-like phenotype 
Short hairpin RNA knockdown of Prdx1 was induced in SAFs via lentiviral infection. Loss 
of Prdx1 in SAFs resulted in an altered, more CAF-like phenotype. shPrdx1 SAFs were visually 
more elongated with increased number of spindle-like protrusions (Figure 6A). 
Immunofluorescence microscopy was conducted to visualize the CAF marker, α-smooth muscle 
actin (α-SMA). In Figure 6B, it is clear shPrdx1 SAFs express more α-SMA than do the EV 
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controls. Immunoblot analysis verified the reduction of Prdx1 protein expression in shPrdx1 SAFs 
(Figure 6C). 
 
 
 
Figure 6. Loss of Prdx1 protein expression results in CAF-like phenotype in stromal fibroblasts A) Phase-
contrast microscopy images displaying altered SAF phenotype, shPrdx1 stromal fibroblasts appear more 
CAF-like with more elongated fibroblasts with enhanced protrusions (arrows) compared to EV-control. B) 
Immunofluorescence microscopy for α-SMA expression, shPrdx1 leads to increased α-SMA protein 
expression compared to EV-control. C) Immunoblot confirming reduction of Prdx1 protein expression in 
shPrdx1 SAFs.  N=3 
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2.3.4  Knockdown of Prdx1 in SAFs leads to increased migration  
Loss of Prdx1 in both human and murine SAFs resulted in significantly increased migration 
in transwell assays. In the human SAFs, VI-RMF, there was approximately a two-fold increase in 
transwell migration compared to the EV-control (Figure 7A). A similar migratory phenotype was 
observed in the shPrdx1 BALB/c mouse SAFs; loss of Prdx1 resulted in significantly more 
migration compared to EV-control SAFs. Treatment with increasing doses of H2O2 resulted in a 
significant, sustained elevation of migration in shPrdx1 SAFs. Although not statistically 
significant, with increasing doses of H2O2, the EV-control SAFs trended towards increased 
migration (Figure 7B). The bottoms of the transwell membranes were stained with crystal violet 
and migrated cells were visualized as those stained purple. shPrdx1 BALB/c mouse SAFs migrated 
significantly more than the control EV SAFs (Figure 7C).  
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Figure 7. Loss of Prdx1 leads to significantly increased migration in human and murine SAFs A) shPrdx1 VI-
RMF Human SAFs were significantly more migratory than EV-control SAFs.  B) shPrdx1 BALB/c mouse 
SAFs were significantly more migratory than EV-control SAFs. Treatment with increasing doses of H2O2 
sustained a significant increase in migration compared to the EV SAFs. C) Crystal violet staining of transwell 
membrane for visualization of migrated cells BALB/c SAFs. 
2.4 Discussion 
The tumor microenvironment is comprised of both cellular and non-cellular components, 
for example, fibroblasts and collagen, respectively13, 21, 151, 156. The architecture of the ECM has 
been shown to have a significant influence on critical cellular functions such as proliferation, 
Mean+ SEM 
N=3  
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migration, differentiation and cancer progression13, 20, 21, 147, 158. Aberrant ECM remodeling is a 
hallmark of aggressive cancers13, 20, 81, 158-160. CAFs play an important role in this remodeling, 
mostly because of their ability to deposit matrix proteins such as collagen and fibronectin13.  The 
significant influence of the stroma on the development and progression of a wide range of various 
cancer types has been well supported by a large body of clinical evidence showing that in tissues 
with chronically inflamed stroma, there is a higher incidence of tumor development161-163.  
Histologically, there are striking similarities between the tumor stroma and wound healing 
stroma; both of these environments contain a large population of myofibroblasts9. Myofibroblasts 
are of particular interest in the reactive stroma of cancer because these cells are typically found at 
sites of tissue remodeling. In wound healing, myofibroblasts are generated from granulation of 
tissue fibroblasts and in the context of cancer, carcinoma cells have been shown to induce the 
transformation of normal fibroblasts to reactive myofibroblasts16, 23, 164, 165.  
Myofibroblasts are known to synthesize and secrete components of the ECM such as 
collagen-I, collagen-III, tenascin and versican while also regulating the expression of proteases15, 
16, 37, 51, 52, 81. Production of these matrix components can result in the remodeling of the ECM, 
which can promote cancer cell proliferation, growth, migration and invasion,16, 51, 53, 54, 56, 81, 166. 
The aberrant remodeling that occurs in cancer further supports the critical role myofibroblasts play 
in promoting an environment conducive to tumor progression16. Studies with co-cultures of 
carcinoma and stromal cells revealed that tumor cell migration is always primarily led by a 
fibroblast and that the carcinoma cells migrate within tracks within the ECM trailing behind a 
fibroblast150. Furthermore, the tracks and remodeled collagen generated by the leading fibroblasts 
provide a migratory structure allowing the collective invasion of carcinoma cells, thereby 
promoting tumor progression.  
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The data presented in this chapter describes a similar migratory phenotype, which occurs 
upon loss of Prdx1 in stromal fibroblasts. A significant increase in migration is observed in 
transwell assays in using both human and mouse stromal fibroblasts deficient in Prdx1. This 
migratory phenotype strongly suggests that Prdx1 can function to prevent cancer progression by 
regulation of fibroblast-led migration. In addition to increased migration, loss of Prdx1 also results 
in phenotypic changes, such as elongation and the formation of migratory protrusions, due to 
cytoskeletal remodeling. These phenotypic differences can be appreciated when compared to 
control fibroblasts (Figure 6). Overall, these data define the critical role of Prdx1 in cancer cell 
migration and in tumor progression. Loss of stromal Prdx1 provides a stromal environment 
permissive to cancer progression, allowing ECM matrix remodeling and cancer cell migration to 
occur. In the following chapters we will deeply investigate and characterize the phenotypes and 
mechanisms of Prdx1 mediated breast cancer cell progression and present novel data which further 
support the importance and influence of the ECM on tumor progression and the critical role of 
Prdx1 in preventing metastasis.  
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3.0 Cancer cell conditioned media inactivation of Prdx-1 
3.1 Introduction 
All six Prdx family members share a conserved catalytic cysteine residue on the N-terminal 
region termed the peroxidatic cysteine, Cys52128.  Prdxs 1-4 contain an additional conserved 
cysteine residue on the C- terminal region which is termed the resolving cysteine, Cys 173128.  
With increasing doses of H2O2, Prdxs can become easily over oxidized on the catalytically active 
cysteine from a sulfhydryl to sulfinic to a sulfonic acid167, 168. This observed overoxidation is 
thought to be due to the existence of a thiolate anion on Cys51, while the other cysteine residues, 
Cys71, Cys83 and Cys 173, remain in a protonated state at neutral pH. The catalytic Cys52 is 
extremely reactive with H2O2 to undergo a complete overoxidation to sulfonic acid or to form a 
disulfide bond169. Cellular levels of H2O2 are tightly regulated by peroxidases; Prdxs scavenge low 
concentrations of H2O2 whereas catalase scavenges high concentrations of H2O2119, 128.  Reversible 
inactivation through overoxidation appears to be an adaptation in eukaryotic cells to allow the 
substantial accumulation of H2O2, thereby allowing H2O2-dependent signaling to occur138. 
Inactivation of Prdx1 by H2O2 induced overoxidation has been well described in the literature119, 
167, 170. Growth factor induced phosphorylation and inactivation of Prdx1 on Y194 has only been 
described in the context of wound healing by one study published in 2010138. Because of the 
importance of Prdx1 in the context of cancer cell signaling and migration, in the results presented
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 in this section, we investigate the influence of MB-MDA-231 breast cancer cell conditioned media 
on Prdx1 status in SAFs at the tumor-stroma interface. Here we hypothesize a novel mechanism 
by which Prdx1 can become inactivated via a paracrine loop from cancer-cell secreted factors, 
thereby mediating Prdx1-dependent collagen remodeling.  
3.2 Materials and methods 
3.2.1  Cell Culture Conditions  
Primary SAFs were isolated from female BALB/c mouse mammary glands as previously 
described in Chapter 2. SAFs were cultured at 37 °C in a 5% CO2 and 5% oxygen incubator.  
3.2.2  Lentivirus Preparation and Infection 
Lentivirus of pLKO.1 shRNA vector specific to Prdx1 was prepared in 293T HEK cells in 
OPTI-MEM Reduced Serum Media.  The shRNA Prdx1 target sequence used was,  
5’CCGGGCTCAGGATTATGGAGTCCTACTCGAGTAAGACTCCATAATCCTGAGCTTTT
TG-3’. Following 24 h, the media was exchanged to 10% FBS-DMEM media and virus was 
collected at 24 and 48 h. Parental SAFs were then infected with 8 μg/mL polybrene in the media. 
Following initial infection, media was exchanged and 7 days post-infection cells were placed under 
a puromycin selection (2 μg/mL) in 10% FBS-DMEM media. 
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3.2.3  Immunoblot 
SAFs were lysed in a TRIS lysis buffer (50mM Tris; 2% Triton X-100; 0.5 mM EDTA; 
0.5 mM EGTA; 150 mM NaCl; 10% glycerol; 50 mM NaF; 1 mM NaVO4; 40 mM β-
glycerophosphate), supplemented with 30 μg/mL catalase from bovine liver (Sigma), and 
proteinase inhibitors. Protein concentrations were quantified using the Pierce BCA Protein Assay 
kit, according to the manufacturer’s instructions (ThermoFisher). Whole cell lysates were 
separated by SDS-PAGE and transferred to a nitrocellulose membrane according to manufacturer 
(BioRad). Membranes were blocked with 5% BSA in TBS for 2 h, and incubated with antibodies 
against phospho-Prdx1-Y194 (1:1000; Cell Signaling), Prdx1 (1:1000; Abcam), Prdx-SO3 
(1:1000; Abcam), and β-Actin (1:1000; Abcam), pSrc (Cell Signaling; 1:1000), Src (Cell 
Signaling; 1:1000) overnight at 4 °C with rocking. Membranes were washed three times for 10 
min in TBST (0.05% Tween-20), and visualized by IR detection. For IR processing, membranes 
were incubated with a 1:15000 dilution of anti-goat, anti-rabbit, or anti-mouse IRDye (LI-COR), 
for 30 min at 25˚ C. Blots were washed with TBST 3 times and with TBS once, and imaged on an 
Odyssey (LI-COR) imager. Membranes processed by chemiluminescence were incubated in a 
1:1000 dilution of HRP-conjugated TrueBlot (Rockland) anti-mouse or anti-rabbit antibodies for 
1 h at 25˚ C. Blots were washed three times with TBST for 5 min, and exposed to ECL for 1 min. 
3.2.4  Statistical Analysis 
Student’s t-test was used to compare two groups. Data are presented as mean +/- SEM. 
Statistical analyses were done using GraphPad Prism. p-value < 0.05 was considered significant. 
Data reported are representative images of at least 3 biologic replicates, n > 3. 
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3.3 Results 
3.3.1  Prdx1 inactivation occurs at tumor-stroma interface 
Prdx1 is hypothesized to become inactivated at the tumor-stroma interface via cancer-cell 
secreted factors. We initially thought that Prdx1 was inactivated via a H2O2-dependent mechanism 
of overoxidation to Prdx-SO3. Data will be presented in this section revealing a novel mechanism 
of Prdx1 inactivation in the context of breast cancer (Figure 8). 
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Figure 8. Schematic of hypothesized mechanism of Prdx1 inactivation Under basal conditions, stromal Prdx1 
activity is high. In progressive metastatic disease and cancer load, stromal Prdx1 activity is low leading to 
increased ECM and collagen remodeling. There are two possible mechanisms of Prdx1; (Top) Cancer-cell 
secreted H2O2 inactivates Prdx1 to Prdx-SO3. (Bottom) Cancer-cell secreted growth factor inactivates Prdx1 
via phosphorylation on Y194. 
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3.3.2  Prdx1 is not inactivated via MBA-MD-231 conditioned media in a H2O2-dependent 
manner 
As described previously, Prdx1 can become inactivated by a H2O2-dependent mechanism 
or by phosphorylation on Y194119, 138, 167, 170. Based on literature suggesting that ROS are an 
important contributor to CAF evolution, we initially hypothesized that breast cancer cells secrete 
H2O2, which inactivates Prdx1 in fibroblasts and causes fibroblast migration and cancer cell 
metastasis. To test this, we examined Prdx1 overoxidation upon treatment with MB-MDA-231 
breast cancer cell conditioned media. The results were striking; inactivation of Prdx1 did not occur 
via H2O2 –dependent overoxidation (Figure 9). 
 
 
 
Figure 9. Prdx1 inactivation does not occur via overoxidation by H2O2 Treatment with cancer conditioned 
media (MCF-7 & MDA-MB-231) does not cause overoxidation (Prdx-SO3). Positive controls for oxidation are 
100 and 250 μM H2O2. N=6 
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3.3.3  Prdx1 is inactivated via phosphorylation on Y194 by MDA-MB-231 cancer cell 
secreted factors. 
Prdx1 can become inactivated via phosphorylation on Y194 as was described previously 
in the context of wound healing138.  Here, we have shown that phosphorylation of Prdx1 occurs in 
the context of breast cancer. Using both non-aggressive and aggressive breast cancer cell lines, 
MCF-7 and MDA-MB-231, respectively, we show that phosphorylation of Y194 in parental SAFs 
occurs upon treatment with MDA-MB-231 conditioned media and not with MCF-7 conditioned 
media. (Figure 10A,B). Moreover, we show that treatment with MDA-MB-231 conditioned media 
resulted in significantly higher phosphorylation of Y194 in parental SAFs compared to the control 
treated samples (10A,B). Src phosphorylation was also significantly higher in MDA-MB-231 
conditioned media treated SAFs (10 C,D).  
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Figure 10. Prdx1 is inactivated via cancer cell secreted factors by phosphorylation of Y194. A). Prdx1 
inactivation via phosphorylation on Y194 occurs upon treatment with MDA-MB-231 cancer conditioned 
media and not with MCF-7 cancer conditioned. B) Quantification of western blot, MDA-MB-231 conditioned 
media treatment resulted in significantly higher phosphorylation of Y194 compared to control and serum 
treated SAFs. C) Src phosphorylation was also significantly higher in MDA-MB-231 conditioned media 
treated SAFs. D) Quantification of Src-phosphorylation western blot indicating significantly higher pSrc/Src 
in MDA-MB-231 conditioned media treated SAFs compared to control. 
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3.3.4  Prdx1 is inactivated via Src-dependent phosphorylation of Y194  
To further understand the mechanism by which Prdx1-Y194 phosphorylation occurs, we 
pretreated SAFs and MDA-MB-231 conditioned media with 20 μM PP1 and detected by 
immunoblot. PP1 is a Src selective kinase inhibitor which has been used to investigate signaling 
pathways involving Src kinases171.  Upon treatment with 20 μM PP1, there is a significant 
reduction in phosphorylation on Y194 of Prdx1 (Figure 11). Moreover, further supporting our 
hypothesis that pY194-Prdx1 is Src dependent, there is also a significant reduction in pSrc (Figure 
11). Our data thus far shows that the inactivation of Prdx1 is in fact due to breast cancer cell 
secreted factors, either due to a growth factor or H2O2. Overall, we confirm that Src regulates the 
phosphorylation of Prdx1 as shown by our inhibition studies and that phosphorylation is indeed 
due to paracrine signaling from a cancer-cell secreted factor. 
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Figure 11. Y194 phosphorylation of Prdx1 is Src- dependent A) Parental SAFs were seeded at a density of 
5x105 cells per plate and were pre-treated for 2 h with 20 μM PP1 and subsequently treated with MDA-MB-
231 conditioned media for 30 mins. Treatment with PP1 resulted in a significant reduction in both pY194-
Prdx1 and also in pSrc. 
 
 
N=4  
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3.3.5  Three potential pathways for inactivation of Prdx1 
In the data presented, we have explored three potential pathways for Prdx1 inactivation. 
The first and most commonly described in the literature is the H2O2–dependent overoxidation of 
Prdx1, which converts Prdx1 to its sulfonic form (-SO3), inactivating peroxidase activity of Prdx1. 
We initially explored this pathway by treating parental SAFs with MDA-MB-231 conditioned 
media and detecting by immunoblot for Prdx-SO3 (Figure 6). The results clearly showed that Prdx1 
inactivation via H2O2 to overoxidation of Prdx was not the mechanism responsible for Prdx1 
inactivation at the tumor-stroma interface (Figure 12). Next, we explored if inactivation of Prdx1 
was due to phosphorylation on Y194. Treating with conditioned media from both MCF-7 and 
MDA-MB-231 breast cancer cell lines, we evaluated pY194-Prdx1 by immunoblot and found that 
Prdx1 was indeed phosphorylated on Y194, however only by MDA-MB-231 conditioned media 
and not by MCF-7 conditioned media. Moreover, our data suggests that phosphorylation of Prdx1 
occurs via a Src-dependent mechanism. 
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Figure 12. Potential pathways of Prdx1 inactivation Prdx1 can become inactivated by H2O2 causing either 
overoxidation (Prdx-SO3) or via Src activation leading to Prdx1 inactivation via phosphorylation of Y194. 
Prdx1 can also become phosphorylated by growth factor activation of Src leading to inactivation of Prdx1 via 
phosphorylation on Y194. 
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3.4 Discussion 
H2O2 is a metabolic byproduct of cellular respiration and has been generally considered 
toxic to cells; however, evidence has emerged suggesting that the production of such reactive 
oxygen species (ROS) play a critical role in membrane-receptor signaling128, 156, 157, 172-174. Prdx1 
is a peroxidase whose main function is to scavenge excess H2O2, however, upon exposure to high 
concentrations of H2O2, Prdx1 becomes overoxidized and loses its peroxidatic and scavenging 
capability106, 113, 128, 155-157, 175. This inactivation of Prdx1 allows for the transient accumulation of 
H2O2 in cellular membranes allowing signaling to occur119, 167, 170, 172.  
As discussed in previous chapters, the most widely accepted mode of Prdx1 inactivation is 
via overoxidation to Prdx1-SO3. Another route by which Prdx1 can become inactivated is by 
phosphorylation of Y194; to date, there has only been one study which describes phosphorylation 
of Prdx1 on Y194 in the context of the wound healing edge138.  In this chapter, we describe a novel 
mechanism of Prdx1 inactivation via phosphorylation of Y194 (pY194-Prdx1) in the context of 
breast cancer.  
Our finding is of critical translational importance because of its influence on cancer 
metastasis and migration. Here we investigated the signaling that takes place at the tumor-stroma 
interface. Initially, we hypothesized that the highly aggressive breast cancer cell line, MDA-MB-
231, would inactivate Prdx1 by H2O2-mediated overoxidation of its catalytic cysteine; however, 
we discovered that this did not occur (Figure 9). On the contrary, as described in Figure 10, Prdx1 
became inactivated via phosphorylation of Prdx1on Y194. This finding suggested that Prdx1 either 
became inactivated by a cancer secreted growth factor, causing the activation of Src and ultimately 
leading to the phosphorylation of Prdx1 or via H2O2-mediated Src activation causing 
phosphorylation of Prdx1 (Figure 12). In the context of wound healing, Prdx1is transiently 
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phosphorylated during active wound regeneration and once the wound is healed, phosphorylation 
of Prdx1 is no longer observed138. The data presented in this chapter illustrates a mechanism by 
which a MBA-MD-231 breast cancer-cell secreted factor inactivates Prdx1, rendering it 
catalytically inactive, thereby, permitting a host of tumor permissive events to occur, which will 
be discussed in detail in chapter 4. Because cancer is typically described as a wound, which does 
not heal, this observation is of particular interest when exploring the signaling dynamics of the 
tumor and surrounding stromal interface of the ECM.  
To delve deeper into understanding how MDA-MB-231 breast cancer cells regulate 
phosphorylation of Prdx1, we treated SAFs with both the Src inhibitor, PP1 (Figure 11). These 
results suggested that inactivation of Prdx1 by phosphorylation of Y194 was most likely due to a 
breast cancer-cell secreted growth factor or H2O2 leading to SRC activation and ultimately Prdx1 
inactivation via phosphorylation. Two likely candidates, as described in the context of wound 
healing, are epidermal growth factor (EGF) or platelet derived growth factor (PDGF)138. 
Abnormal accumulation of ROS in tumor epithelial cells, inducing aberrant signaling 
cascades and leading to oncogenic phenotypes has been well-described147, 156, 176. Moreover, ROS 
can also affect the cellular composition of fibroblasts in the tumor stroma of the ECM by 
transforming them into CAFs176. Based on our finding thus far, we have established that 
phosphorylation-dependent inactivation of Prdx1 is mediated by an MBA-MD-231 breast cancer 
cell-secreted factor. H2O2, is a known activator of Src, therefore, it is also possible that 
phosphorylation of Prdx1 is due to H2O2, activation of Src, leading Src-mediated catalytic 
inactivation of Prdx1 via phosphorylation.  
Our data suggest that inactivation of Prdx1 via phosphorylation could be a mechanism to 
allow for an aberrant accumulation of H2O2, further promoting a carcinogenic environment and 
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supporting the metastatic potential of breast cancer cells. In normal circumstances, such as wound 
healing, a transient elevation in H2O2 allows the activation of wound regeneration cascades which 
resolve upon conclusion of wound activation, however, in the context of cancer, this is not the 
case20, 27, 138.
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4.0  In vivo prdx1 regulation of collagen architecture and extracellular matrix remodeling 
in the mammary gland  
4.1 Introduction 
The mammary gland is composed of both epithelial and stromal cells, which communicate 
via ECM interactions. Maintenance of tightly regulated epithelial and stromal communication is 
essential for normal mammary morphogenesis. Interferences with these signals can both promote 
and induce breast cancer progression177. Human breast tumors are notably stiffer than normal 
tissues; this characteristic has now been used to detect and classify tumor grade and 
invasiveness178.   
Collagen remodeling in the ECM has been well studied in the context of breast cancer. 
Architectural modifications of collagen fibers from curly, anisotropic orientations to linear and 
stiff fibers has been established as a hallmark of breast cancer aggressive potential; the mechanism 
behind this phenomenon, however, has yet to be fully understood51-54, 79, 81, 179.  Collagen-I is the 
most abundant protein is mammals71, 74. Crosslinking of two α-collagen chains between triple 
helical domains results in the formation of pepsin-resistant β-dimers of collagen, characterized as, 
β11, β12 and β22180. Isolated crosslinked collagen β-dimers, were found to be robustly fluorescent, 
a phenotypic characteristic of collagen in aged tissues180.  To date, extensive evidence has emerged 
implicating the ECM in governing the progression of metastases. Collagen crosslinks that are seen 
in remodeled stromal matrices of the tumor microenvironment provide carcinoma cells a structural  
scaffold promoting cancer progression52-54, 56, 179. Furthermore, in collagen remodeled ECM, 
carcinoma cells have been shown to migrate along linearized collagen fibers acting as a highway 
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or track, trailing behind a leading fibroblast150. Because activated fibroblasts are known to deposit 
ECM proteins such as collagen21, 156, we hypothesized that loss of Prdx1 in stromal fibroblasts 
could function to promote ECM remodeling and thereby, induce cancer cell migration. 
4.2 Materials and Methods 
4.2.1  Syngeneic Mouse Model of Breast Cancer Metastasis 
A BALB/c syngeneic mouse model was designed to evaluate tumor cell migration and 
ECM remodeling in vivo. Knockdown PRDX1 SAFs were generated through expression of 3’ 
UTR-targeted shPrdx1. In initial studies, BALB/c SAFs (shPrdx1 or control vector) expressing 
iRFP were co-injected into the 4th inguinal mammary fat pad and 8-days post-injection, glands 
were harvested and fixed in 2% paraformaldehyde for 2 h and subsequently stored in 0.02% 
sodium azide-PBS solution. Following fixation, tissues were imaged using second harmonic 
generation (SHG) and multiphoton microscopy (MPM). 
4.2.2  Second Harmonic Generation and Multiphoton Microscopy 
Multiphoton microscopy with second harmonic generation on an Olympus FV1000 with 
multiphoton excitation (Tokyo, Japan) equipped with a Spectra-Physics DeepSee Mai Tai Ti–
Sapphire laser (Newport, Mountain View, CA) with an 1.12NA 259 MPE water immersion 
objective was used to visualize collagen, elastin, iRFP and GFP.  
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4.2.3  Lentiviral shPrdx1 iRFP and GFP 
Lentiviral infection of SAFs with shPrdx1 RNA was conducted as previously described in 
chapter 2. Infrared- red fluorescent protein (iRFP) and green fluorescent protein (GFP) were 
expressed into shPrdx1 SAFs via lentiviral infection. 7-days post infection, iRFP and GFP 
expressing SAFs were placed under hygromycin selection and subsequently expanded.  
4.2.4  Collagen Quantification (in vivo) 
Collagen deposition was quantified using ImageJ. A z-projection of 40 slices was 
maximally projected in an 8-bit image of the collagen only channel and locations of high tumor 
load (green) were quantified for collagen intensity in week 1 and week 2 injected mammary glands. 
4.2.5  In Vitro Collagen Deposition Assay 
Parental SAFs were plated in 12-well plates at a seeding density of 3 x104 cells per well in 
10% FBS-DMEM media. Cells were incubated at 37 °C in a 5% CO2 incubator for  
6-days to allow for cellular crowding and collagen deposition. On day 6, cell layers were washed 
twice with 1X HBSS and collagen was extracted from cell layers via acidic porcine pepsin 
digestion as described previously81, 181.  Protein samples were separated using SDS-PAGE with a 
7% acrylamide resolving gel, under non-reducing conditions. Protein bands were stained using the 
Silver Quest kit (Invitrogen). 
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4.2.6  LOX Secretion 
Scramble and knockdown SAFs were plated at a density of 1x105 cells per 10-cm plate. 
Cells were serum starved in DMEM for 24 h. Following the 24 h starve, conditioned media was 
collected and secreted proteins were precipitated by trichloroacetic acid (TCA) precipitation as 
previously described182. Following TCA treatment, precipitates were washed twice with acetone 
and allowed to air dry for 10 mins. Pellets were then resuspended in 20 µl 2X Laemli sample buffer 
and prepared for SDS-PAGE. 
4.2.7  Immunoprecipitation 
HEK 293T cells (5 x 105) were transiently transfected with 2 µg pcDNA3-FLAG-LOX1 
and pcDNA3-FLAG-LOXL2 plasmids, using the Fugene 6 system for 48 h. Cells were serum 
starved for 30 min, then treated with 100 µM H2O2 for 30 min. Prior to lysis, cells were washed 
one time with PBS containing 20 mM of NEM (N-ethylmaleimide) to avoid oxidation of free 
thiols. Samples were lysed using a TRIS lysis buffer (50mM Tris; 2% Triton X-100; 0.5 mM 
EDTA; 0.5 mM EGTA; 150 mM NaCl; 10% glycerol; 50 mM NaF; 1 mM NaVO4; 40 mM β-
glycerophosphate), supplemented with 30 µg/ml catalase from bovine liver (Sigma), and 
proteinase inhibitors. Protein concentrations were quantified using the Pierce BCA Protein Assay 
kit, according to the manufacturer’s instructions (Thermo). 1 mg of cell lysate was incubated with 
20 µL of acid treated Anti-FLAG M2 Affinity Gel (Sigma) and 400 µL lysis buffer, at 25˚ C for 3 
h, with rotation. Precipitated samples were collected and washed four times with lysis buffer, and 
once with 1x TBS. Beads were boiled in Laemmli sample buffer (BioRad) in the presence or 
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absence of β-mercaptoethanol (Sigma) for 10 min. 20 µg of whole cell lysate was prepared in 
Laemmli sample buffer as above for 5 min. 
4.3 Results 
4.3.1  Extracellular Matrix Remodeling in a Syngeneic Mouse Model 
To further understand the relationship between CAFs, the tumor microenvironment and 
breast cancer metastasis, we developed a syngeneic BALB/c mouse model. Using 8-week old 
female, non-parous mice, we injected iRFP expressing EV-control and iRFP-shPrdx1 SAFs into 
the mammary fat pad and at days 2, 4, 6 and 8 following injection, the glands were imaged using 
multiphoton microscopy/ second harmonic generation (MPM/SHG) microscopy (Figure 13A). 
MPM/SHG microscopy allows for the visualization of endogenous, repetitive structures such as 
collagen and elastin using second harmonic generation. Using MPM/SHG microscopy, collagen 
is illuminated as blue, iRFP SAFs as red and Elastin as green. In Figure 13B, a negative control, 
non-injected mammary gland shows typical adipose structures that are found in normal mice. On 
Day 2 post- injection of iRFP-EV SAFs, collagen deposition is noted, however, re-organization is 
not seen (Figure 13C). 2 days following injection, reorganization and deposition of collagen and 
elastin can be seen in glands injected with iRFP-shPrdx1 SAFs (Figure 13D). 6 days post-injection, 
significantly more collagen remodeling can be visualized in iRFP-shPrdx1 injected glands 
compared to iRFP-EV injected glands (Figure 13 E, F). To visualize migratory potential of 
shPrdx1 SAFs in vivo, images of distance travelled from injection site were compiled. iRFP-
shPrdx1 SAFs migrated further away from the injection site (Figure 10H) compared to iRFP-EV 
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SAFs (Figure 13G). Overall, this data suggests that Prdx1 regulates ECM collagen remodeling and 
that loss of Prdx1 function promotes metastasis by contributing to collagen remodeling, 
reorganization and deposition. 
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Figure 13. Loss of Prdx1 results in collagen remodeling and reorganization in vivo A) Schematic of syngeneic 
mouse model design. iRFP expressing, EV-control and shPrdx1 SAFs were injected at a density of 1x106 cells 
into the 4th inguinal mammary fat pad of BALB/c mice. Mammary glands were harvested on days 2, 4, 6 and 
8 post-injection. Mammary glands were fixed in 2% PFA and prepared for MPM/SHG microscopy. B) 
Negative control, non-injected mammary gland showing endogenous adipose structures, C) iRFP-EV SAF 
injected gland, 2 days post injection, D) iRFP-shPrdx1 injected gland, 2 days post injection, E) iRFP-EV SAF 
injected gland, 6 days post injection, F) iRFP-shPrdx1 injected gland, 6 days post injection, G) Day 8 
compiled image of SAF migration from injection site, iRFP-EV, F) iRFP-shPrdx1. Collagen=blue, Green= 
Elastin, Red= iRFP expressing SAFs, Yellow= Merge. N=3 
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4.3.2  Collagen fiber remodeling and reorganization in mammary gland 
In the previous section we show data, which suggests that loss of Prdx1 in SAFs contributes 
to collagen and ECM remodeling. To understand if loss of Prdx1 in SAFs could contribute to breast 
cancer cell migration, using the same syngeneic mouse model described in section 4.3.1, we 
introduced a GFP expressing, non-metastatic mouse breast cancer cell line, GFP-67NR and co-
injected with the iRFP expressing EV and shPrdx1 SAFs. Mammary glands were processed as 
described in the last section and were harvested for MPM/SHG imaging at 1-week and 2-weeks 
post-injection (Figure 14A). At 1 week post-injection, there was a striking difference in behavior 
of the GFP-67NR non-metastatic breast cancer cells. Co-injection of iRFP-EV + GFP-67NR 
resulted in the formation of a localized tumor surrounded by curly collagen bundles (Figure 14B). 
However, injection of GFP-67NR + iRFP-shPrdx1 resulted in the dispersal of the cancer cells and 
linearized collagen fibers (Figure 14C).   
This reorganization, remodeling and cancer cell dispersion further suggested that Prdx1 is 
a key regulator of the tumor microenvironment. Loss of Prdx1 results in remarkable alterations in 
the behavior of typically non-metastatic breast cancer cells and in the structure and integrity of the 
stromal microenvironment. Tumoral collagen was quantified using a 40 μM z-stack of the collagen 
channel where there was a high localization of GFP-67NR breast cancer cells in the injected glands 
(Figure 15A). Tumoral collagen was significantly higher in GFP-67NR+ iRFP-shPrdx1 injected 
glands compared to GFP-67NR+iRFP-EV injected glands (Figure 15 B-F). Tumor-Associated 
Collagen Signatures (TACS) were evaluated in the MPM in vivo images. Although not significant, 
mammary glands with a co-injection of shPrdx1 SAFs and GFP67NR breast cancer cells showed 
a trend toward an increased TACS-3 phenotype (Figure 16). 
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Figure 14. Loss of Prdx1 in SAFs promotes migration of non-metastatic breast cancer cells and ECM 
remodeling.  A) Syngeneic mouse model, co-injection of GFP-67NR and iRFP-EV/iRFP-shPrdx1 SAFs into 
the 4th inguinal mammary fat pad. Glands were harvested at 1-week and 2-weeks and were processed for 
MPM/SHG imaging. B) 1-week post injection, iRFP-EV + GFP-67NR injected glands resulted in localized 
tumor formation surrounded by curl, relaxed collagen bundles. C). 1-week post injection, iRFP-shPrdx1 + 
GFP-67NR injected glands resulted in migration of GFP-67NR breast cancer cells and remodeling of the 
microenvironment to linearized collagen fibers. N=3 
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Figure 15. Quantification of tumoral collagen deposition  A) z-projection of 40 slices was quantified for 
collagen deposition, B) Green indicates areas of high localization of GFP-67NR cells with iRFP-EV SAF con-
injection, C) 8-bit image of only collagen channel in GFP-67NR + iRFP-EV injected glands, D) Green 
indicates areas of high localization of GFP-67NR cells with iRFP-shPrdx1 SAF co-injection, E) 8-bit image of 
only collagen channel in GFP-67NR + iRFP-shPrdx1 injected glands, F) Quantification of collagen fiber 
deposition. 1-week post injection of GFP-67NR+ iRFP-shPrdx1 injected glands resulted in significantly 
higher collagen deposited compared to GFP-67NR+iRFP-EV injected glands. Week 2 collagen deposition 
trended higher in GFP-67NR+ iRFP-shPrdx1, although not significant. 
Mean+ SEM 
N=3  
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Figure 16. TACS Quantification of Remodeled Collagen in Mammary Gland A) Schematic of TACS-1/TACS-
2/TACS-3 characteristics, B,C) EV SAF + GFP67NR injected mammary gland 1–week post injection, 
collagen-only channel as 8-bit image, respectively, D,E) shPrdx1 + GFP67NR injected mammary gland 1-
week post injection, collagen-only channel as 8-bit image, respectively, F) Quantification of TACS- grading 
by three blinded evaluators, N=3. 
 
 
4.3.3  Prdx1 regulates collagen crosslinking via lysyl oxidase 
Based on the in vivo data presented in the previous sections, we wanted to better understand 
the mechanism behind the remodeling of the tumor stroma that occurs when Prdx1 is absent. To 
address this question, we plated Scramble, shPrdx1#2 and shPrdx1#4 SAFs and allowed them to 
deposit collagen over a period of 6 days, we then performed a pepsin digest, ran samples on an 
SDS-PAGE gel and lastly stained for varying collagen bundles using silver stain (Figure 17A). 
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The results clearly showed that loss of Prdx1 led to increased levels of β11 and β12 crosslinked 
collagen as well as elevated levels of α1 and α2 non-crosslinked collagen (Figure 17B). Lysyl 
oxidase (LOX) is widely accepted to be the primary enzyme responsible for collagen crosslinking. 
To determine if the Prdx1 regulation of collagen crosslinking is dependent on LOX, we treated 
with βAPN, a widely used LOX inhibitor. The results clearly showed a significant reduction in 
β11 and β12 and a significant increase in α1 and α2 (Figure 17C).  Moreover, when investigated 
the amount of LOX secreted from the SAFs into the ECM, it was clear that loss of Prdx1 in the 
shPrdx1 SAFs, resulted in a significant increase in LOX secretion compared to the Scramble 
control (Figure 17 D).  
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Figure 17. Prdx1 regulates LOX-dependent collagen remodeling and secretion A) Collagen deposition assay- 
SAFs were plated at a seeding density of 1x106 cells.  Over a 6-Day period, the SAFs deposited collagen onto 
the plate. The cell layer was pepsin digested and subsequently run on an SDS-PAGE for silver staining. B) 
Loss of Prdx1 results in significant increase of β11 and β12 crosslinked collagen as well as elevated levels of 
α1 and α2 non-crosslinked collagen. C) Treatment with βAPN, a LOX inhibitor, resulted in a significant 
reduction in β11 and β12 and a significant increase in α1 and α2. D) Loss of Prdx1 also resulted in a 
significant increase in LOX secretion to the ECM compared to scramble control. 
Mean+ SEM 
n=3  
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4.3.4  Prdx1 binds LOX and LOXL2 in a H2O2 -Independent Manner 
Prdx1 has already been identified as a promiscuous binding partner for a wide range of 
signaling proteins128. Prdx1 is known to regulate the signaling proteins, c-Abl, c-Myc, ASK-1 and 
JNK via direct binding of Prdx1174, 183-186. However, Prdx1 regulation of collagen crosslinking 
enzymes such as LOX has not been previously explored. Based on the results we presented thus 
far, we decided to investigate whether Prdx1 directly binds to LOX, thereby regulating its function. 
To determine this, using 293T HEK cells we transfected FLAG-LOX and detected Prdx1-LOX 
binding by immunoblot. The co-immunoprecipitation results clearly showed that there was a direct 
binding interaction of Prdx1-LOX compared to the EV control (Figure 18A). Previous studies have 
established that Prdx1 binding with c-Myc and JNK can be interrupted with increasing doses of 
H2O2187, 188. To explore if Prdx1-LOX binding is H2O2-dependent, we treated the transfected 
FLAG-LOX samples for co-immunoprecipitation samples with 100μM H2O2. The results clearly 
indicated that PRDX1-LOX binding was not disrupted by H2O2 (Figure 18B). This suggested that 
the binding and regulation of LOX by Prdx1 was independent of H2O2 status. Another family of 
the LOXs which has been implicated in breast cancer progression is the lysyl oxidase-like 2 protein 
(LOXL2)60. Because LOX and LOXL2 have similar functions with respect to collagen 
crosslinking, we examined the binding interaction of Prdx1-LOXL2 with and without H2O2 
treatment. The results, again, clearly showed that Prdx1 does directly bind to LOXL2 and it also 
showed that this interaction is independent of H2O2 concentrations (Figure 18 C, D). 
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Figure 18. Prdx1 regulates LOX and LOXL2 via direct binding A) FLAG-LOX was transfected into 293T 
cells and co-immunoprecipitation was conducted. Direct binding of Prdx1-LOX was detected by immunoblot. 
B) FLAG-LOX binding was not interrupted by H2O2 treatment. C) Prdx1-LOXL2 co-immunoprecipitation, 
D) H2O2 treatment of Prdx1-LOXL2 co-immunoprecipitation. N=3 
 
4.4 Discussion 
The ECM is an invaluable regulator of tissue and cellular function in an organism and the 
disciplined control of its homeostasis is essential to normal functions such as wound healing and 
development. However, perpetual dysregulation of this homeostasis can lead to potentially fatal 
pathological conditions such as fibrotic disease and metastatic cancer39, 160, 189. Tumor development 
is a complex and dynamic process which involves cellular signals intrinsic to the cancer cells 
themselves and also extracellular, environmental cues which can significantly influence the 
progression of a cancer to metastasis160, 189. Cells with a tumorigenic phenotype have been shown 
to revert back to a normal phenotype by manipulation of the tumor microenvironment, suggesting 
that the metastatic potential of tumors is very much influenced by the ECM163.  
Architectural rearrangements of the ECM, for the most part, due to increased LOX activity 
has long been correlated with poor prognosis and increased metastasis and invasiveness of many 
cancer cell types160. Although ROS and ECM remodeling in the context of cancer have been well 
studied, the relationship between the two at the tumor-stroma interface has yet to be 
comprehensively studied. To address this issue, we first evaluated the role of Prdx1 in ECM 
remodeling in vivo. The results provided a striking phenotype of collagen linearization and 
alignment (Figure 13). This supported our hypothesis that loss of Prdx1 resulted in increased 
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collagen remodeling. Typically, normal stroma can function to delay and prevent tumorigenesis 
while aberrantly activated stroma can function to promote cancer progression163.  Previous studies 
have shown that co-cultivation of stromal cells with primary breast carcinoma cells caused the 
tumor cells to become invasive and more migratory163. Furthermore, when Prdx1 levels were 
compared in stromal versus epithelial tissues, Prdx1were significantly higher in stromal tumor 
associated tissues. 
To investigate if we could recapitulate this finding in the context of ROS, using a syngeneic 
mouse model we co-injected iRFP expressing EV/ shPrdx1 SAFs with GFP expressing 67NR 
breast cancer cells. 67NR breast cancer cells were selected because they are characterized as a 
non-aggressive and non-metastatic breast cancer cell line. Since we were examining the influence 
of stromal fibroblasts on cancer cell migration, we wanted to see if co-injection with shPrdx1 SAFs 
could indeed stimulate migration and invasion in these typically non-invasive breast cancer cells. 
The results of this study were again, striking. As shown in figure 14, co-injection of iRFP-shPrdx1 
SAFs with GFP-67NR breast cancer cells resulted in dispersion and migration of the breast cancer 
cells (Figure 14C, green) with increased linearized collagen (Figure14C, blue). In control injected 
mammary glands, the GFP expressing 67NR breast cancer cells remained localized as a primary 
tumor with minimal collagen remodeling (Figure 14B). These findings further supported our 
hypothesis that Prdx1 had a functional role in the regulation of the ECM at the tumor stroma 
interface. Furthermore, for the first time, our findings provided novel evidence that stromal ECM 
homeostasis was partly regulated by a peroxidase, Prdx1. Moreover, when tumoral collagen was 
quantified, it became clear that loss of Prdx1 resulted in significantly more collagen deposition 
compared to the EV control (Figure 15-16).  
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With the findings from our in vivo data, we decided to first, examine if Prdx1 status could 
directly influence collagen crosslinking and remodeling and second, determine if LOX was the 
enzyme responsible for this remodeled collagen phenotype. Using the cellular crowding and 
collagen deposition assay, we found that loss of Prdx1 in SAFs resulted in elevated levels of β11 
and β12 crosslinked collagen compared to scramble control (Figure 17B). Moreover, when treated 
with the LOX inhibitor, βAPN, levels of β11 and β12 crosslinked collagen decreased while non-
crosslinked α1,2 levels increased (Figure 17C). It is of interest to note that typically, collagen 
deposition by fibroblasts is a slow process, in some cases taking over 1-month181. Our shPrdx1 
stromal fibroblasts were able to deposit collagen matrix rapidly, taking only 6-days in the absence 
of any crowding agent. Furthermore, when LOX secretion was evaluated, we found that loss of 
Prdx1 in SAFs led to a significant increase in LOX secretion to the ECM (Figure 17D). Lastly, the 
direct binding of Prdx1 to LOX and LOXL2, independent of H2O2 status suggested that Prdx1 
sequesters LOX and LOXL2 inside the cell by direct binding, preventing its secretion to the ECM 
(Figure18). 
When exploring tumor-stroma dynamics, it’s important to note that H2O2 is a known 
byproduct of LOX activity37, 46, 58. Previous studies have shown that removal of H2O2 by catalase 
treatment in invasive breast cancer cells resulted in loss of Src activation58. Moreover, when treated 
with βAPN, an established LOX inhibitor, Src activation was decreased58. This supports our 
hypothesis that inactivation of Prdx1 by Src activation results in ECM remodeling. In this chapter, 
we presented data that provides an important link between the importance of Prdx1 peroxidase 
activity and ECM collagen remodeling and stromal reorganization.  
These data suggest and support the critical role of Prdx1 in regulating a tumor 
microenvironment, which is not permissive to metastasis. It has long been known that fibrotic 
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signals enrich tumor progression, however, the underlying mechanism behind this phenomenon is 
not yet fully understood. The data presented in this chapter provide novel insight into mechanisms 
of ECM dysregulation and collagen remodeling and place Prdx1 as a central regulator of LOX-
dependent collagen remodeling in the tumor microenvironment. Our data highlight the important 
clinical implications for the treatment of stromal fibrosis in the tumor microenvironment and it is 
the first to link LOX-mediated architectural changes of the tumor ECM to a peroxidase.  
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5.0 General Discussion and Future Directions 
Increasing evidence in the field of metastasis support the important role of the stroma and 
ECM in the progression of various different types of cancer. Several decades of in-depth research 
on breast cancer has been mostly focused on tumor cell autonomous properties. Only recently, has 
the field began to accept and appreciate the important role of the ECM and tumor stroma on cancer 
progression and metastasis. The ECM is characterized as a fertile ground for fibroblast recruitment, 
matrix deposition and for enhanced cancer cell-stroma communications190.  
In normal conditions, the stromal component of the ECM provides structural support and 
maintenance of tissue homeostasis, however, in the context of breast cancer, the stroma undergoes 
architectural changes via the recruitment of activated fibroblasts, enhancing aberrant stromal 
dynamics such an increased collagen deposition and fiber modifications. Modifications to the 
structure of collagen have been shown to serve as a network or highway thereby, promoting cancer 
cell migration51, 52. Although increased collagen deposition and fiber remodeling leading to 
elevated mammographic breast density78 has long been correlated as a risk factor for the 
development of breast cancer, the mechanism behind this phenomenon was not well characterized.  
The data presented in this dissertation provide novel insight into 1) understanding the 
functional dynamics of the tumor-stroma in relation the architectural modifications of the ECM 
and its significance in the context of breast cancer progression and 2) characterizing the mechanism 
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and key proteins involved in regulating matrix deposition and collagen remodeling via cancer-cell- 
stroma paracrine signaling, resulting in Prdx1 inactivation. 
As described in chapters 2 and 3, Prdx1 has been established as a critical modulator of ROS 
homeostasis in the cytosol of the cell. Prdx1 is a peroxidase, which, when catalytically active, 
functions as a H2O2 scavenger. Most evidence in the field to date has served to classify and define 
Prdx1 inactivation via overoxidation of its catalytic cysteine by high doses of H2O2 (> 100 μM). 
Our initial hypothesis focused on cancer-cell secreted H2O2 as the mechanism by which stromal 
Prdx1 became inactivated. However, our initial experiments quickly confirmed that this did not 
occur. In fact, later experiments presented in chapter 3 showed that Prdx1 was inactivated via 
phosphorylation on Y194 in parental stromal fibroblasts. This was mediated by a paracrine breast 
cancer-cell secreted factor from MBA-MD-231breast cancer cells. Furthermore, this secreted 
factor was most likely either by a growth factor or H2O2, however, both could result in the 
phosphorylation and activation of SRC leading to the inactivation of Prdx1.  
Inactivation of Prdx1 via phosphorylation of Y194 via an MBA-MD-231 breast cancer-
cell secreted factor is a novel finding, which has not yet been observed or characterized in the field. 
This is of critical importance in the context of better understanding breast cancer metastasis and 
how early cancer cell paracrine signaling to stromal fibroblasts can lead to a cascade of events, 
starting with stromal Prdx1 inactivation via phosphorylation. This inactivation of Prdx1 leads to 
the localized accumulation of H2O2, which thereby suggests, that neighboring normal stromal 
fibroblasts can also then become activated due to further inactivation of stromal Prdx1. This 
positive feedback loop between MBA-MD-231 cancer-cell secreted factors suggests a mechanistic 
explanation of how an activated fibroblast can sustain itself without regression to basal level.  
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Furthermore, in this dissertation we show that sustained fibroblast activation via cancer-
cell paracrine signaling leading to Prdx1 inactivation via phosphorylation, results in a cascade of 
ECM remodeling events, such as significantly increased collagen deposition and LOX secretion, 
both in vivo and in vitro. To better understand the metastatic potential of stromal Prdx1 
inactivation, studies would need to be conducted in vivo to evaluate metastatic spread of shPrdx1 
fibroblasts and breast cancer cells to distant sites in the body, such as the bone and lung, the two 
most common sites of breast metastases. Moreover, in terms of clinical and translational relevance, 
use of LOX inhibitors in combination with chemotherapy may be of value in targeting and 
preventing breast cancer metastases. Use of LOX inhibitors, such as tetrathiomolybdate, a potent 
copper chelator, in the treatment of various types of cancer, has shown limited or poor success. 
However, recent reports from a small phase-II clinical trial with tetrathiomolybdate, has shown 
that 62 of 75 patients with advanced breast cancer had no detectable evidence of disease at 5 
years191. This further suggests that considering treatment with LOX inhibitors may be a viable 
therapeutic option to prevent breast cancer progression.  
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Appendix 
 
 
Figure 19: Supplemental Figure 1 Immunoblot of shPrdx1 knockdown constructs and protein levels and 
proliferation curve of scramble, shPrdx1#2 and shPrdx1#4 SAFs. 
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